Veru (VERU) Non-Current Deferred Tax Liability (2010 - 2024)
Veru (VERU) posted quarterly Non-Current Deferred Tax Liability of $395736.0 for Q3 2024, down 12.28% year-over-year from $451159.0 in Q4 2023, and down 12.28% quarter-over-quarter from $451159.0 in Q3 2023.
Veru (VERU) Non-Current Deferred Tax Liability (2010 - 2024) Analysis & Trends
Veru (VERU) has reported Non-Current Deferred Tax Liability for 15 consecutive years, with $395736.0 the latest figure, recorded in Q3 2024.
- In Q3 2024, Non-Current Deferred Tax Liability fell 12.28% year-over-year to $395736.0; the TTM figure through Sep 2024 stood at $395736.0 (down 12.28% YoY), while the FY2024 annual figure was $395736.0, down 12.28% from the prior year.
- Non-Current Deferred Tax Liability declined to $395736.0 in Q3 2024 per VERU's latest filing, from $451159.0 in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $451159.0 in Q3 2023 and bottomed at $63426.0 in Q3 2021.
- Historically, Non-Current Deferred Tax Liability has averaged $152380.9 across 5 years, with a median of $74724.0 in 2020.
- Annual changes were most pronounced in 2020 — Non-Current Deferred Tax Liability plunged 98.18% — and 2023, when it jumped 456.53%.
- Veru's Non-Current Deferred Tax Liability stood at $74724.0 in 2020, then retreated by 15.12% to $63426.0 in 2021, then changed by 0.0% to $63426.0 in 2022, then surged by 611.32% to $451159.0 in 2023, then slipped by 12.28% to $395736.0 in 2024.
- Business Quant data shows VERU's Non-Current Deferred Tax Liability at $395736.0 in Q3 2024, $451159.0 in Q3 2023, and $63426.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Veru | 60.85 Mn | 35.06 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 395,736.00 |
| Sep 30, 2024 | 395,736.00 |
| Sep 30, 2023 | 451,159.00 |
| Sep 30, 2023 | 451,159.00 |
| Dec 31, 2022 | 63,426.00 |
| Dec 31, 2022 | 63,426.00 |
| Sep 30, 2022 | 81,067.00 |
| Sep 30, 2022 | 81,067.00 |
| Jun 30, 2022 | 63,426.00 |
| Jun 30, 2022 | 63,426.00 |
| Mar 31, 2022 | 63,426.00 |
| Mar 31, 2022 | 63,426.00 |
| Dec 31, 2021 | 63,426.00 |
| Dec 31, 2021 | 63,426.00 |
| Sep 30, 2021 | 63,426.00 |
| Sep 30, 2021 | 63,426.00 |
| Jun 30, 2021 | 74,724.00 |
| Jun 30, 2021 | 74,724.00 |
| Mar 31, 2021 | 74,724.00 |
| Mar 31, 2021 | 74,724.00 |